Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab trial in non-small cell lung cancer patients with ECOG performance status 2
ISRCTN10047797Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Sep 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Birmingham. Primary endpoints: Toxicity and Response rate. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN10047797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10047797.